Consistent with in vitro data and the results of our recent studies [40], we also found that ALDH1A1 and ALDH1A3 are differently associated with BRFS and MFS in patients with high-risk locally advanced PCa treated with ADT, and high ALDH1A1 expression is significantly associated with worse outcomes. The gene discussed is ALDH1A3; the disease is posterior cortical atrophy.